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Abstract
O-Linked -N-acetylgalactosamine (O-GalNAc) glycans constitute a major part of the human 
glycome. They are difficult to study because of the complex interplay of 20 distinct 
glycosyltransferase isoenzymes that initiate this form of glycosylation, the polypeptide N-
acetylgalactosaminyltransferases (GalNAc-Ts). Despite proven disease relevance, correlating the 
activity of individual GalNAc-Ts with biological function remains challenging due to a lack of tools 
to probe their substrate specificity in a complex biological environment. Here, we develop a “bump–
hole” chemical reporter system for studying GalNAc-T activity in vitro. Individual GalNAc-Ts were 
rationally engineered to contain an enlarged active site (hole) and probed with a newly-synthesized 
collection of 20 (bumped) uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) analogs to 
identify enzyme–substrate pairs that retain peptide specificities but are otherwise completely 
orthogonal to native enzyme–substrate pairs. The approach was applicable to multiple GalNAc-T 
isoenzymes, including GalNAc-T1 and -T2 that prefer non-glycosylated peptide substrates and 
GalNAcT-10 that prefers a pre-glycosylated peptide substrate. A detailed investigation of enzyme 
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kinetics and specificities revealed the robustness of the approach to faithfully report on GalNAc-T 
activity and paves the way for studying substrate specificities in living systems.
Introduction
Glycosylation with O-linked -N-acetylgalactosamine (O-GalNAc), historically called mucin-type O-
glycosylation, is one of the most abundant forms of post-translational modification in higher 
eukaryotes1 and is essential for normal embryonic development,2 immune cell function,3 and 
metabolic homeostasis.4 Aberrations in O-GalNAc glycosylation are associated with tumor 
progression.5 Accordingly, the enzymes that initiate O-GalNAc glycosylation, the polypeptide N-
acetylgalactosaminyltransferases (GalNAc-Ts), are differentially regulated, and their expression has 
been associated with various disease states.6–9 The human genome encodes 20 GalNAc-T paralogs, 
constituting one of the largest and arguably most complex glycosyltransferase families.10 GalNAc-Ts 
are membrane-associated, type II Golgi-resident enzymes with adjacent catalytic and lectin domains 
that face the Golgi lumen. Some isoenzymes seem to share functional redundancies, as reflected in 
subtle animal knockout phenotypes,11,12 whereas others are essential for viability or specific organ 
functions.2,13
 
O-GalNAc glycans frequently decorate proteins in clusters called mucin glycodomains.14 These 
densely glycosylated regions are built by sequential action of GalNAc-Ts that glycosylate unmodified 
or sparsely O-GalNAc glycosylated peptide sequences (e.g., GalNAc-T1 and -T2), and GalNAc-Ts 
that follow-up initial glycosylation by other GalNAc-Ts and act adjacent to existing O-GalNAc 
glycans (e.g., GalNAc-T10).10,15 The substrate specificities of the various isoenzymes collectively 
create an O-GalNAc glycoproteome with discrete biological consequences.
Despite their participation in many facets of human biology, our understanding of GalNAc-T 
substrate selection is limited. GalNAc-Ts transfer a GalNAc residue from the nucleotide sugar donor 
uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) to the hydroxyl groups of Ser, Thr, and 
possibly Tyr residues of proteins in the secretory pathway and supposedly the nucleus.16,17 GalNAc-Ts 
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contain an N-terminal catalytic domain and a C-terminal lectin domain, and the interplay between 
these two domains determines the acceptor substrate specificity of different GalNAc-T 
isoenzymes.18,19 Peptide-preferring GalNAc-Ts utilize the lectin domain to install a new GalNAc 
residue away from an existing GalNAc on a glycopeptide (6 to 17 residues in the N- or C-terminal 
direction).18 In addition to this long-range GalNAc recognition by the lectin domain, glycopeptide-
preferring GalNAc-Ts can install a GalNAc adjacent to nearby GalNAc residues on a glycopeptide, 
which is attributed to an additional GalNAc binding site in the catalytic domain.20 
Due to the complex mechanism modulating glycosite specificities, the protein substrates and 
particular glycosylation sites modified by individual GalNAc-Ts are not well described, hampering 
our understanding of their biological function and disease causality. Classical genetic approaches 
toward understanding GalNAc-T function are complicated by protein substrate redundancies and the 
existence of overlapping protein target sites.12,21 More targeted genetic studies have validated roles for 
GalNAc-T2 glycosylation of ApoCIII and ANGPTL3 in high-density lipoprotein metabolism,9 
GalNAc-T3 glycosylation of FGF23 in familial tumoral calcinosis,22 and GalNAc-T11 glycosylation 
of Notch in heterotaxy, associated with congenital heart disease.13 Despite these forays, the primary 
source of information about specific amino acid preferences of individual GalNAc-Ts is still the 
performance of in vitro assays with peptide substrates.18,23,24
Clausen and co-workers made a major breakthrough in discerning GalNAc-T substrate specificity 
using cell lines engineered to generate O-GalNAc glycoproteins displaying truncated glycans with 
limited elaborations.25 Glycoproteomics analyses of these so-called SimpleCells – with and without a 
single GalNAc-T knockout – identified isoenzyme-specific glycosylated proteins and sites.21,26–28 
However, given the interdependencies and substrate redundancies of various GalNAc-Ts, it is likely 
that the absence of a single GalNAc-T employed in this loss of function approach does not provide a 
complete picture of the roles of individual enzymes in this family. Furthermore, due to the truncated 
glycan structures found on SimpleCells and cancer cells, and the associated oncogenic phenotype, the 
substrate specificities of GalNAc-Ts in this context may not be fully representative of their behavior 
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in non-cancerous cells.5,28 A powerful addition to the field would be a method that enables the 
identification of the protein substrates of an individual GalNAc-T in the presence of the full repertoire 
of glycosyltransferases and GalNAc-Ts, including the GalNAc-T of interest, that are normally found 
in the cell or model system.
We envisioned a complementary approach in which individual GalNAc-T isoenzymes are engineered 
to acquire a gain of function – the ability to accept a substrate analog that marks their specific protein 
substrates and glycosites with a chemical handle. Key to this “bump–hole” engineering strategy is the 
identification of gatekeeper residues that can be mutated to alter the active site so as to accommodate 
a modified substrate.29 Critically, this “bumped” substrate should not be recognized by native 
members of the enzyme family, so as to remove false-positive signals generated by other endogenous 
GalNAc-T isoenzymes. A fully orthogonal system—in which the engineered enzyme utilizes the 
bumped substrate analog with high efficiency, while no longer recognizing the native substrate—may 
also benefit from a high signal-to-noise ratio. The bump–hole strategy has been successful with other 
enzyme families, including kinases,30,31 acetyltransferases,32 methyltransferases,33 and ADP-
ribosyltransferases.34
Previous studies have demonstrated that glycosyltransferases are amenable to enzyme–substrate 
engineering, wherein the active site is modified to accept a non-native substrate.35 Of particular 
relevance, the enzymes -1,4-galactosyltransferase 1 (4Gal-T1) and O-linked -N-
acetylglucosamine transferase (O-GlcNAc transferase) have been rationally designed to accommodate 
nucleotide sugars bearing chemical handles.36–38 Both of these engineered glycosyltransferases 
demonstrate expanded substrate specificity, as they still use their native substrates, UDP-galactose 
and UDP-GlcNAc, respectively.36,37 These engineered enzyme–substrate pairs have been successfully 
employed to study proteins modified with O-GlcNAc.36,38 Application of orthogonal bump–hole 
engineering across glycosyltransferase families has the potential to yield new insights into critical 
biology.
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Here, we report a strategy for engineering orthogonal GalNAc-T and UDP-sugar pairs that can, in 
principle, be applied across the enzyme family (Scheme 1). We identified a combination of active site 
point mutations that caused loss of function with UDP-GalNAc but gain of function with synthetic 
UDP-GalNAc analogs that contain a chemical handle. We found orthogonal enzyme–substrate pairs 
that retained peptide glycosylation site preferences and catalytic parameters comparable to their native 
counterparts. The generality of the strategy was demonstrated with bump–hole pairs for the peptide-
preferring GalNAc-Ts, -T1 and -T2, and a glycopeptide-preferring GalNAc-T, -T10.
Scheme 1.  A Bump–Hole Approacha
aMutagenesis of key gatekeeper residues in the active site of a GalNAc-T introduces a “hole” in the catalytic domain 
of the engineered GalNAc-T that accommodates an enlarged UDP-GalNAc analog modified with a “bump” (orange 
circle) and chemical handle (orange diamond). The N-acyl side chain of UDP-GalNAc contains a methyl group (red 
Me) that is modified on the UDP-GalNAc analog to an R-group (red R), representing the bump and chemical handle. 
Monosaccharides are represented with colored boxes: GalNAc (yellow) and GalNAc analog (orange). The lectin 
domain of a GalNAc-T is represented as semicircle (dashed line).
Results and Discussion
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To identify potential gatekeeper residues to target for mutagenesis, we analyzed the available crystal 
structures of the catalytic and lectin domains of GalNAc-T1,39 -T2,40–42 and -T10,43 some of which 
contained bound GalNAc or UDP-GalNAc in the active site. We considered different positions 
around GalNAc when selecting a location in the active site for mutagenesis. Notably, we previously 
found that virtually all GalNAc-T isoenzymes can use UDP-N-azidoacetylgalactosamine (UDP-
GalNAz) as a substrate both in vitro and in living cells or organisms, albeit with reduced efficiency 
compared to UDP-GalNAc.44–46 Thus, we anticipated that larger N-acyl substituents would be required 
to avoid recognition by wild-type GalNAc-T isoenzymes, and these would have to be accommodated 
by an engineered active site hole. We noted a high degree of conservation of three hydrophobic 
residues within 5 Å of the methyl group of GalNAc that create a binding pocket (Figure 1). We 
hypothesized that some combination of I253, L310, and F361 could serve as active site gatekeeper 
residues across the enzyme family (Figures 1 and S1). To test these hypotheses, we initially focused 
on GalNAc-T2, an isoenzyme that prefers to modify unglycosylated peptide substrates and is one of 
the best characterized of the family.40–42 
F361
I253
UDP-GalNAc
Me
Mn2+ H359
D224
L310
Me
F361
L310 UDP-GalNAc
Me
A                                                     C
B 
Residue(T2): 253 310 361
T16 --SPIIDVI--  --AGGIFVI--  --GHVFRKR--   
T14 --CPVIDII--  --AGGLFVI--  --GHVFRKK--
T2 --SPIIDVI--  --AGGLFVM--  --GHVFRKQ-- 
T13 --CPIIDVI--  --AGGLFSI--  --GHVFRKA--
T1 --CPIIDVI--  --AGGLFSI--  --GHVFRKA-- 
*T12 --CPVIDVI--  --AGGLFAV--  --GHVFPKQ-- 
*T4 --CPVIDTI--  --AGGLFAV--  --GHVFPKR--  
T6 --SPDIVTI--  --AGGLFSI--  --GHVFRTK--
T3 --SPDIASI--  --AGGLFSI--  --GHVFRSK--  
T15 --SPVIDVI--  --PGEVVAM--  --GHIYQNQ-- 
T20 --CPLIDVI--  --SGGIFAI--  --GHISKKQ--  
T11 --CPVIDII--  --AGGLFAM--  --GHIFRKR--
T5 --CPVIEVI--  --AGGLFSI--  --GHIFRND--
*T7 --VPLIDVI--  --AGGLFAI--  --GHIYRLE--
*T17 --CPMIDVI--  --AGGLFAV--  --GHIYRKY--  
*T10 --CPMIDVI--  --AGGLFAV--  --GHIYRKY--
T19 --LPSIDNI--  --IGCSFVV--  --AHIERKK-- 
T9 --LPAIDNI--  --IGCSFVV--  --AHIERTR--
T18 --SPSFDNI--  --IG-CFIV--  --AHIERAH-- 
T8 --SPVFDNI--  --MG-ILAA--  --AHLERHH--
I253
Figure 1.  Identification of gatekeeper residues. (A) Residues within 5Å of GalNAc methyl carbon for GalNAc-T2 
(PDB ID: 4D0T). Five of seven amino acids in close proximity to the GalNAc methyl contain side chains; of these, 
H359 and D224 coordinate Mn2+, while I253, L310, and F361 are promising hydrophobic residues. (B) Space-filling 
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model of gatekeeper residues within 5Å of GalNAc methyl in GalNAc-T2 (PDB ID: 4D0T). (C) Amino acid 
sequences of human GalNAc-T1–GalNAc-T20 surrounding potential gatekeeper residues demonstrate a high degree 
of conservation, with 13 isoenzymes containing I253/L310 and 18 containing I253. Only GalNAc-T8 and -T18 have 
dramatically different residues at position 253 and around 310. GalNAc-Ts used in this study are boxed. Clustal 
Omega was used to generate a multiple sequence alignment of the amino acid sequences corresponding to the full-
length genes of human GalNAc-T1–GalNAc-T20 (Figure S2; Table S1). GalNAc-Ts are ordered based on homology, 
and GalNAc-Ts that predominantly prefer GalNAc-peptides are denoted with an asterisk.10 
Prior to generating the bump–hole pair, we considered the risk that our proposed GalNAc 
modifications would interfere with the ability of downstream GalNAc-Ts to glycosylate GalNAc 
analog-modified proteins. The lectin domain is critical to most follow-up GalNAc-T glycosylation, so 
we evaluated the binding mode of the GalNAc-T2 lectin domain with a GalNAc-peptide, MUC5AC-
13.42 We observed that the methyl group of GalNAc extends out of a pocket—created by the acceptor 
peptide and the lectin domain—and into a large, solvent exposed cleft (Figure S3). This crystal 
structure suggests that N-acyl-modified GalNAc analogs might not experience a steric clash in the 
lectin domain of GalNAc-Ts with a similar binding mode for GalNAc-peptides.
We generated four single point mutants (I253A, L310A, F361A, and F361S) and one double mutant 
(I253A/L310A) of a soluble, FLAG epitope-tagged GalNAc-T2 construct containing the catalytic and 
lectin domains and secreted from mammalian cells.47 Preliminary screens with purified proteins and 
the known peptide substrate EA2-biotin (PTTDSTTPAPTTKK(biotin))46 showed minimal activity 
from either F361 mutant with UDP-GalNAc (1) or UDP-GalNAz (2),46,48 in line with mutagenesis 
data that were published thereafter.42 The remaining three mutants (I253A, L310A, and 
I253A/L310A) and wild-type GalNAc-T2 were investigated further.
We next designed a quantitative enzymatic assay with the sensitivity and flexibility necessary to 
accommodate chemically diverse UDP-GalNAc analog libraries and measure kinetic parameters of 
mutated GalNAc-Ts. Widely-used glycosyltransferase assays rely on the detection of UDP as a side 
product of the glycosylation reaction.49 Although we used this method for initial screens (Figures S4 
and S5), we deemed it of limited utility, as background hydrolysis of UDP-sugars under these 
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conditions produces UDP that limits sensitivity. The assay had to be independent of the nature of the 
chemical handle, precluding the use of our previously developed azido-ELISA (enzyme-linked 
immunosorbent assay).50 We therefore used the chromophore 2,4-dinitrophenyl-5-L-alanine amide, 
which was installed on peptide substrates using Marfey’s reagent and is convenient to monitor by UV 
detection during high-performance liquid chromatography (HPLC). We prepared an artificial, labeled 
peptide via solid-phase peptide synthesis as an optimal GalNAc-T2 substrate (Peptide-1) based on 
previously identified amino acid preferences (Figure 2A).23 
O
AcO
OAc
ClH3N
AcO
OAc
O
AcO
OAc
NH
AcO
OR'
R
O
O
AcO
OAc
HN
AcO
R
O O P
O
OH
OH
O
HO
OH
HN
HO
R
O O UDP
B
O
HO
OH
H2N
HO
O UDP
O
O
R
N
O
O
O
HO
HO
OH
O
OP
O
O
ONa
P
O
O
ONa
OHOH
N
NH
O
O
R = Me N3 N3 N3 N3
Me Me Et
N3
Et
N3
Bn
N3
Bn
N3
CH2OMe
N3
CH2OMe
N3 N3 N3
N3
Me Me
Me Me
Me Me
Me
1 2 (S)-3 (R)-3 (S)-4 (R)-4
(S)-5 (R)-5 (S)-6 (R)-6
(R)-8 (S)-8 9 10
11 (R)-12 (S)-12
13 (R)-14 (S)-14
N3
7
O
HN
R
C
Marfey's Reagent, a)
then deprotection,
cleavage
F
O2N
NO2
NH
Me
CONH2
A
GAGAPGPTPGPAGAGKH2N GAGAPGPTPGPAGAGK COOH(DAA)HN
Peptide-1
DAA = NH
NO2
O2N
CONH2
Me
Marfey's Reagent =
= ClTrt resin
c)
d)
b)
f)
+
e)
g)
Route 2
Route 1
=R' -Ac
=R' H
=R' -PO(OAll)2
Figure 2.  Synthesis of a peptide substrate and a panel of UDP-GalNAc analogs. (A) Synthetic route for Peptide-1. 
Blue T indicates the Thr glycosylation site used by GalNAc-T2. (B) Synthetic routes for UDP-GalNAc analogs. Route 
1 was used to synthesize UDP-sugars ((S)-3, (R)-3, (S)-4, (R)-4, (S)-5, (R)-5, (S)-6, (R)-6, (S)-8, (R)-8, (S)-12, (R)-12, 
(S)-14, (R)-14), and Route 2 was used to synthesize UDP-sugars (2, 7, 9, 10, 11, 13). (C) A panel of UDP-GalNAc 
derivatives with azide or alkyne chemical handles. Compounds 1 and 2 are the natural substrate UDP-GalNAc and 
known analog UDP-GalNAz, respectively. Reagents and conditions: a) NEt(i-Pr)2, DMF, r.t.; b) R-COOH, COMU®, 
NEt(i-Pr)2, DMF, 0 °C to r.t.; c) N,N’-dimethyl-1,3-diaminopropane, THF, r.t.; d) i-Pr2NPO(OAll)2, 1H-tetrazole, 
CH2Cl2, 0 °C, then m-CPBA, −78 °C; e) Pd(PPh3)4, sodium p-toluenesulfinate, THF/MeOH, r.t.; f) i. Uridine 5′-
monophosphomorpholidate 4-morpholine-N,N′-dicyclohexylcarboxamidine salt, 1-methylimidazole hydrochloride, 
NEt3, DMF, r.t.; ii. MeOH/water/NEt3, r.t.; g) HEPES buffer (pH = 8.0), 0 °C to r.t.
We next synthesized a collection of UDP-GalNAc analogs, chemically diversified at the C2-
acylamide moiety and including bioorthogonal azide or alkyne groups. Synthesis of nucleotide sugars 
is nontrivial, and both chemical and enzymatic routes have been developed.50–54 As UDP-GalNAc 
biosynthetic enzymes are unlikely to accommodate all envisaged modifications,51,55 we chose to 
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chemically synthesize 20 bumped UDP-GalNAc analogs by two routes adapted from literature 
procedures (Figure 2B).50,53,56 Installation of the acylamide side chain into a UDP-galactosamine 
scaffold via active ester chemistry proceeded smoothly to provide compounds 2, 7, 9, 10, 11, and 13 
(Figure 2B, Route 2). For UDP-GalNAc analogs containing chiral acylamide α-carbon atoms, an 
alternate route was selected to minimize the risk of acylamide epimerization during installation. Thus, 
acylamides were introduced at an early stage in the syntheses of compounds ((S)-3, (R)-3, (S)-4, (R)-4, 
(S)-5, (R)-5, (S)-6, (R)-6, (S)-8, (R)-8, (S)-12, (R)-12, (S)-14, (R)-14) (Figure 2B, Route 1), using 
COMU® as a highly efficient coupling reagent that precluded epimerization. Together, these two 
routes and an optimized purification procedure enabled us to generate a structurally diverse panel of 
synthetic UDP-GalNAc analogs (Figure 2C).
With purified enzymes, synthetic peptide substrate, and UDP-GalNAc analogs in hand, we assessed 
the viability of GalNAc-T bump–hole engineering in a combinatorial fashion, using an HPLC-based 
enzymatic assay (Figure 3A). Wild-type GalNAc-T2 efficiently transferred a GalNAc residue from 
UDP-GalNAc (1) to the acceptor peptide, and the single mutants T2(I253A) and T2(L310A) still 
utilized UDP-GalNAc as a donor substrate, although with reduced activity (Figure 3B). In contrast, 
UDP-GalNAc was a poor substrate for the double mutant enzyme T2(I253A/L310A), which we felt 
might allow for the development of an orthogonal GalNAc-T and UDP-sugar pair. 
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Figure 3.  Screening GalNAc-T2 for an orthogonal enzyme–substrate pair. (A) Scheme for glycosylation reaction 
with Peptide-1, GalNAc-T2, and UDP-GalNAc or UDP-GalNAc analog to form glycosylated Peptide-1. Blue T 
indicates the Thr glycosylation site used by GalNAc-T2. (B) Glycopeptide formation by wild-type and mutant 
GalNAc-T2. UDP-GalNAc and Peptide-1 were incubated with GalNAc-T2 at 37 °C for 1 h, and the reaction was 
quenched by the addition of aqueous EDTA (150 mM, pH = 8.0). The percent conversion to glycopeptide product was 
quantified by HPLC separation and peak integration. All data represent the mean of technical triplicates, and the error 
bars represent the standard deviation. (C) Bump–hole pair optimization for GalNAc-T2. Glycosylation by wild-type 
and double mutant GalNAc-T2 was compared for UDP-GalNAc (1) and UDP-GalNAc analogs with Peptide-1. 
Reactions were performed and quantified as in B. Heat map (blue shading) shows percent glycosylated Peptide-1 
formed by wild-type or double mutant GalNAc-T2 with UDP-GalNAc or analogs. Red values represent the mean of 
technical triplicates.
We investigated how enlargement of the GalNAc side chain alters substrate activity for the wild-type 
and double mutant enzymes (Figures 3C and S6 for selected UDP-GalNAc analogs and Figure S4 for 
additional analogs). UDP-GalNAz (2) was a better substrate for wild-type GalNAc-T2 than for the 
double mutant T2(I253A/L310A). Strikingly, however, some UDP-GalNAc analogs with longer or 
branched N-acyl chains were better substrates for T2(I253A/L310A) than for wild-type GalNAc-T2. 
These included UDP-GalNAc analogs with additional alkyl substituents  to the amide as in (S)-3 and 
(S)-4, longer side chains as in 7, 11 (“UDP-GalNAlk”),57 and 13, or both branches and length as in 
(S)-12, (R)-12, (S)-14, and (R)-14. For analogs 11–14, we observed that as the size of the alkyne-
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containing bump increased, wild-type enzyme activity plummeted. In contrast, the double mutant 
enzyme maintained activity with these larger alkyne-functionalized UDP-GalNAc analogs. In the 
extreme case of (R)-14, glycopeptide formation by the wild-type enzyme was undetectable, while the 
double mutant still produced glycopeptide product. 
An orthogonal enzyme–substrate pair should ideally retain the catalytic efficiency of the native 
enzyme–substrate pair to appropriately emulate biological function. Michaelis–Menten kinetic 
analysis revealed that both native and bump–hole enzyme–substrate pairs had comparable kinetic 
parameters (Table 1). Catalytic constants (kcat) of enzyme–substrate pairs T2(I253A/L310A) and (S)-
3, 7, 11, or (S)-12 differed less than two-fold from the wild-type GalNAc-T2/1 pair. The kcat of the 
engineered pair T2(I253A/L310A)/13 was approximately five-fold lower. Concomitantly, this pair 
displayed a ten-fold lower Km compared to the wild-type pair, suggesting that 13 benefitted from 
increased contacts within the active site leading to stronger substrate binding. Thus, the catalytic 
efficiency (kcat/Km) of T2(I253A/L310A)/13 is two-fold higher than wild-type GalNAc-T2/1. In 
contrast, (S)-12 exhibited the weakest interaction with T2(I253A/L310A) among all enzyme–substrate 
pairs tested, with a ten-fold higher Km than the wild-type pair, suggesting that the methyl branch at the 
acylamide α-position experiences a steric clash with the enzyme. 
Table 1.  Kinetic parameters of wild-type and engineered GalNAc-T2 and UDP-sugar pairs.a 
 
aTo determine Km and kcat values for UDP-GalNAc and UDP-GalNAc analogs, initial rates were measured by 
incubating wild-type or double mutant GalNAc-T2 with concentrations of UDP-sugars varying from 15.6 M to 500 
M and with a constant concentration of acceptor peptide (Peptide-1 = 267 M for 1, (S)-3, 11; Peptide-1 = 250 M 
for 7, (S)-12, 13). The glycosylation was conducted at 37 C, and three aliquots were taken within 15 min and 
quenched by the addition of aqueous EDTA (150 mM, pH = 8.0). Products were quantified by HPLC separation and 
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peak integration. The enzymatic kinetic parameters were obtained by nonlinear regression fitting using GraphPad 
Prism. All data represent the mean of technical triplicates, and error depicts the standard deviation.
To enable potential application in biological systems, wild-type GalNAc-Ts must not accept bumped 
UDP-GalNAc analogs in the presence of UDP-GalNAc. We examined the relative selectivity of wild-
type GalNAc-T2 toward UDP-GalNAc compared to selected analogs (Figure 4). Competition 
experiments revealed that in the presence of a 1:1 mixture of UDP-GalNAc and either UDP-GalNAc 
analog (S)-3, 7, 11, or 13, wild-type GalNAc-T2 indeed preferentially transferred GalNAc to Peptide-
1. In the reaction that included analog 13, the glycopeptide product observed was almost exclusively 
that derived from UDP-GalNAc.
Figure 4.  Selectivity of wild-type GalNAc-T2 for UDP-GalNAc relative to UDP-GalNAc analogs. (A) Scheme 
for competition experiment between UDP-GalNAc and UDP-GalNAc analog. Wild-type GalNAc-T2 was treated with 
Peptide-1 and an equal ratio of UDP-GalNAc and UDP-GalNAc analog in a competition experiment, and 
glycosylation reactions were terminated at 20–30% glycopeptide formation. (B) Selectivity of wild-type GalNAc-T2 
for UDP-GalNAc (1) over UDP-GalNAc analog ((S)-3, 7, 11, or 13) in a competition experiment. Reactions were 
performed as in A. UDP-sugars and Peptide-1 were incubated with GalNAc-T2 at 37 °C for 30 min, and the reaction 
was quenched by the addition of aqueous EDTA (150 mM, pH = 8.0). The percent conversion to glycopeptide product 
was quantified by HPLC separation and peak integration. Percent of Peptide-1 modified with GalNAc or GalNAc 
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analog was measured, and the selectivity ratio is shown in blue. All data represent the mean of technical triplicates, 
and the error bars represent the standard deviation. 
We next sought to determine if our bump–hole strategy could be generalized to study other members 
of the GalNAc-T family. We thus extended the approach to GalNAc-T1, a peptide-preferring 
isoenzyme that is phylogenetically distant from GalNAc-T2, and GalNAc-T10, an isoenzyme that 
prefers glycosylated substrates and, as such, is particularly difficult to study in vivo.10,28 We generated 
wild-type and double mutant versions of GalNAc-T1 and -T10 using the same methods and 
gatekeeper residues homologous to GalNAc-T2 (I238A/L295A for -T1, I266A/L321A for -T10). We 
designed and prepared acceptor substrates labeled with 2,4-dinitrophenyl-5-L-alanine amide in the 
same fashion as Peptide-1. Similar to GalNAc-T2, amino acid preferences of GalNAc-T1 have been 
studied, and we used an optimized sequence for Peptide-2, which contains a single threonine for 
glycosylation (Figure 5A).23 GalNAc-T10, as a glycopeptide-preferring isoenzyme, required a pre-
installed GalNAc directly adjacent C-terminally to the glycosylation site. To this end, MUC5AC-3, a 
known GalNAc-T10 glycopeptide substrate, was used as the sequence for Peptide-3 (Figure 5A).12,58
Gratifyingly, the bump–hole approach developed for GalNAc-T2 was directly transferrable to both 
GalNAc-T isoenzymes, despite their distinct substrate preferences. Wild-type GalNAc-T1 efficiently 
catalyzed glycosylation with UDP-GalNAc, whereas minimal activity was observed with UDP-
GalNAc analog 13 (Figure 5B). In contrast, T1(I238A/L295A) did not utilize UDP-GalNAc as a 
substrate but efficiently transferred the modified GalNAc residue from analog 13 to Peptide-2 
(Figures 5B and S5). Similar to GalNAc-T2 engineering, the kcat of T1(I238A/L295A) with 13 was 
approximately five-fold lower than the kcat of wild-type GalNAc-T1 with UDP-GalNAc (Figure 5C). 
In contrast, the Km value was unaltered, resulting in a reduction of catalytic efficiency by less than an 
order of magnitude (Figure 5C). The selectivity of GalNAc-T10 showed identical trends; the 
preference of wild-type GalNAc-T10 for UDP-GalNAc over 13 was reversed in the double mutant 
T10(I266A/L321A), highlighting the universality of our bump–hole approach for multiple members 
of the GalNAc-T family with diverse peptide and glycopeptide substrate preferences (Figure 5B). 
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Mutation of I266 and L321 to alanine residues had no effect on the kcat and conferred only a two-fold 
higher Km with the UDP-sugar analog, despite a switch in specificity from UDP-GalNAc to 13 
(Figure 5C). 
Peptide-2:
peptide
T
GAGAFFPTPGPAGAGK COOH(DAA)HN
GalNAc-T1 (Peptide-2)
or
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Figure 5.  Orthogonal GalNAc-T and UDP-sugar pairs for GalNAc-T1 and GalNAc-T10. (A) Scheme for 
glycosylation reaction with GalNAc-T, peptide, and UDP-GalNAc or UDP-GalNAc analog to form glycosylated 
peptide. Glycosylation reactions with GalNAc-T1 utilized Peptide-2, and reactions with GalNAc-T10 utilized Peptide-
3. Blue T indicates the Thr glycosylation site used by the GalNAc-T of interest. (B) Glycopeptide formation by wild-
type or double mutant GalNAc-T1 or GalNAc-T10 with UDP-GalNAc (1)  or 13. Reactions were performed as in A. 
GalNAc-T, UDP-sugar, and peptide were incubated at 37 C for 1 h (-T10) or 2 h (-T1), and the reaction was 
quenched with aqueous EDTA (150 mM, pH = 8.0). All data represent the mean of technical triplicates, and the error 
bars represent the standard deviation. (C) Kinetic parameters of wild-type and orthogonal GalNAc-T and UDP-sugar 
pairs. To determine Km and kcat values for UDP-GalNAc and UDP-GalNAc analogs, initial rates were measured by 
incubating wild-type or double mutant GalNAc-Ts with varying concentrations of UDP-sugars and a constant 
concentration of acceptor peptide. For GalNAc-T1, the concentration of UDP-sugars varied from 15.6 M to 500 M, 
and the concentration of acceptor Peptide-2 was held at 250 M. For GalNAc-T10, the concentration of UDP-sugars 
varied from 15.6 M to 250 M, and the concentration of acceptor Peptide-3 was held at 266 M. The glycosylation 
was conducted at 37 C, and three aliquots were taken within 15 min and quenched by the addition of aqueous EDTA 
(150 mM, pH = 8.0). Products were quantified by HPLC separation and peak integration. The enzymatic kinetic 
parameters were obtained by nonlinear regression fitting using GraphPad Prism. All data represent the mean of 
technical triplicates, and error depicts the standard deviation.
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Finally, we explored whether the glycosylation site specificity of all three GalNAc-T bump–hole pairs 
was altered due to the active site mutations we introduced (Figure 6). In contrast to protein substrates, 
the specificities of GalNAc-T isoenzymes toward synthetic peptide substrates have been exhaustively 
mapped and are the basis for recent mechanistic and structural studies.15,18,23,46,59 We performed 
glycosylation reactions with known peptide and/or glycopeptide substrates of GalNAc-T1, -T2 and -
T10, and fragmented and manually sequenced the resulting mono- (GalNAc-T1 and -T2) or di-
glycopeptides (GalNAc-T10) by tandem mass spectrometry to identify site preferences. The 
glycopeptide MUC5AC-3 contains multiple potential glycosylation sites, three of which are 
glycosylated at different frequencies by wild-type GalNAc-T2 and UDP-GalNAc.60 We observed 
similar fine specificities for these sites with the T2(I253A/L310A)/13 pair, with a preference for 
Thr13 over Thr9 and Thr10 (Figure 6B). A similar retention of site specificity was found using other 
known GalNAc-T2 substrates that contain multiple potential glycosylation sites, the glycopeptide 
MUC5AC-13 and the peptide EA2 (Figure 6B).41,60 Because the potential Thr acceptor sites on 
MUC5AC-3 and/or -13 are between 1 and 11 residues from the existing GalNAc residue, these 
glycopeptides enabled us to evaluate the influences of both the catalytic and lectin domains on 
glycosite determination. The glycosylation patterns of MUC5AC-3 and MUC5AC-13 by wild-type 
and double mutant GalNAc-T2 demonstrated similar glycosite specificities for lectin domain-assisted 
glycosylation activity in both the N- and C-terminal directions. 
Glycosylation site specificity was also retained for GalNAc-T1 and -T10 bump–hole pairs, using EA2 
and MUC5AC-3 substrates, respectively (Figure 6B).58,61 Of note, GalNAc-T10 contains a GalNAc 
binding pocket in the catalytic domain directly adjacent to the active site, conferring selectivity 
toward pre-glycosylated substrates.20 The double mutant T10(I266A/L321A) maintains specificity for 
Thr2 of MUC5AC-3, the only Thr adjacent to an existing glycosite, and exhibits minimally altered 
kinetic parameters. Our experiments demonstrate that T10(I266A/L321A) retains its identity as a 
glycopeptide-preferring isoenzyme with the glycopeptide MUC5AC-3, and we anticipate that this 
result will extend to other substrates. 
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Figure 6.  Glycosylation of natural peptide substrates by wild-type and engineered GalNAc-T isoenzyme–
substrate pairs. (A) Scheme for glycosylation reaction with GalNAc-T, natural peptide substrate, and UDP-GalNAc 
or UDP-GalNAc analog to form glycosylated peptide. Glycosylation reactions were terminated at 10–20% 
glycopeptide formation. (B) Percent of glycosylated peptide formed out of total glycosylated peptide formed. 
Reactions were performed as in A at 37 C and quenched by the addition of aqueous EDTA (150 mM, pH = 8.0). 
Naturally-occurring glycopeptides MUC5AC-3 and MUC5AC-13 each contain a single GalNAc-O-Thr (T*). Red T* 
indicates the site of glycosylation by the GalNAc-T of interest. Glycosylation of MUC5AC-3 by GalNAc-T2 yields a 
major product that is glycosylated at Thr3 for wild-type GalNAc-T2/1 and either Thr2 or Thr3 for 
T2(I253A/L310A)/13, labeled (TT)*. (C) Representative MS/MS spectrum of EA2 glycosylated by 
T2(1253A/L310A)/13 upon fragmentation and sequencing. Fragmentation pattern of EA2 amino acid sequence to 
generate c-ions (blue) and z-ions (red) is shown.
Conclusions
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Taken together, these data indicate that GalNAc-T bump–hole pairs retain the glycosylation site fine 
specificities and general kinetic parameters of the native enzyme–substrate pairs among the acceptor 
substrates tested. Such an outcome is promising for application of this technology to the discovery of 
new protein substrates and glycosylation sites in living systems. It is particularly notable that this 
strategy translates successfully to GalNAc-T10, which, as an isoenzyme that prefers glycosylated 
substrates, is notoriously difficult to study. In fact, the first O-GalNAc glycoproteomic analysis of 
GalNAc-T10 was recently reported using the SimpleCell technique.28 However, due to the action of 
GalNAc-T10 adjacent to existing glycosites, the authors did not identify any specific glycoproteins or 
glycosites that could be unambiguously attributed to -T10.28 Due to the presence of a chemical handle 
on the GalNAc analogs described here, the bump–hole system may prove powerful in efforts to assign 
glycosites on densely O-GalNAcylated peptides that arise from follow-up GalNAc-Ts such as 
GalNAc-T10.
In an effort to establish that bump–hole engineering of GalNAc-Ts minimally alters their acceptor 
substrate specificity, we used a small panel of peptides and glycopeptides. Totaled among the three 
GalNAc-Ts studied, we used 5 peptides containing 4 unique amino acid sequences and 2 glycopeptide 
variants of MUC5AC. We found that the wild-type and bump–hole pairs perform very similarly with 
these peptides and glycopeptides. However, because this subset of acceptor substrates represents a 
fraction of the total protein substrates that these enzymes glycosylate in living systems, further work 
will be necessary to validate the performance of these pairs in vivo. Additionally, it will be important 
to uncover whether downstream activity by GalNAc-Ts and elaborating glycosyltransferases is 
observed on glycopeptides modified with these GalNAc analogs. Although GalNAz is known to be 
recognized by glycosyltransferases that elaborate the glycan structure,62 the effect of the bumped N-
acyl group is unknown. Towards these ends, we are currently exploring the application of the 
engineered enzyme–substrate pairs presented here in cells.   
This work represents a robust orthogonal bump–hole system for a glycosyltransferase family, wherein 
the engineered enzymes exclusively use a synthetic substrate analog but do not accept the native 
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substrate. Significantly, the modified substrate is not utilized by native GalNAc-T isoenzymes. Such 
an achievement would not have been possible without structural data, particularly the first structure of 
human GalNAc-T10 bound to GalNAc and UDP reported in 2006.43 Currently, six total GalNAc-T 
family members have been structurally characterized with the addition of several recent crystals,15,63 
establishing a foundation for the identification of promising gatekeeper residues to target for 
mutagenesis. Further forays into structural characterization of other glycosyltransferase families are 
warranted to expand this approach across the larger enzyme superfamily.
It should be noted that, while structure data formed a cornerstone to this study, the ability to 
synthesize and rapidly screen many substrate analogs proved critical to identifying orthogonal bump–
hole pairs. By exploring chemical space around the N-acyl position, we identified substrates with 
exquisite specificity for double mutant GalNAc-Ts. We envision that bump–hole pairs such as those 
described here could be generally applicable across the GalNAc-T family, given their well-conserved 
UDP-GalNAc binding site.10,15 The bump–hole enzyme–substrate pairs we developed here set the 
stage for a new approach to the identification of biological substrates of GalNAc-Ts in living systems, 
analogous to work done with other enzyme families.29,64,65
Methods
Expression of GalNAc-Ts. The soluble domains of GalNAc-T2, -T1, and -T10 include both the 
catalytic and lectin domains, and the design of our mammalian secretion constructs were based on 
published constructs.47 These truncated constructs were cloned into pFLAG-myc-CMV19, containing 
an N-terminal preprotrypsin leader sequence and an N-terminal FLAG tag. Mutations in GalNAc-T2 
and -T1 were introduced using site-directed mutagenesis and mutations in -T10 were introduced 
during gene synthesis (Table S2).
Truncated GalNAc-Ts were expressed in HEK-293T cells and purified from the culture medium by 
FLAG affinity chromatography. Glycerol was added to purified proteins to a final concentration of 
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25% (v/v). Proteins were quantified by densitometry of Coomassie-stained SDS-PAGE gel bands, 
aliquoted and stored at 80 °C. Western blot confirmed the identity of FLAG-tagged GalNAc-Ts 
(Figure S7).
Representative experimental procedure for the preparation of UDP-N-acetyl--D-galactosamine 
derivatives (Figure 2B). Route 1: 1,3,4,6-Tetra-O-acetyl-2-amino-2-deoxy-β-D-galactopyranose 
hydrochloride and azido acids were prepared according to literature procedures. A mixture of 1,3,4,6-
tetra-O-acetyl-2-amino-2-deoxy-β-D-galactopyranose (192 mg, 0.500 mmol), the azido acid (0.500 
mmol), and Hünig’s base (0.261 mL, 1.50 mmol) in DMF (4.00 mL) in a 25-mL round-bottom flask 
was cooled to 0 °C. COMU® was added, and the reaction mixture was stirred at 0 °C for 1 h. The 
solution was allowed to warm to r.t. and stirred for 3 h. The mixture was diluted by the addition of 
ethyl acetate (50 mL), rinsed with HCl (1 M; 2 x 10 mL), saturated aqueous NaHCO3 (2 x 10 mL), 
and brine (20 mL), dried over Na2SO4, and concentrated. The product was purified by column 
chromatography. 
Diallyl galactosyl 1-phosphates were prepared and deallylated according to a literature procedure.66 
Tri-O-acetylated UDP-sugars were prepared by treating sugar 1-phosphates (0.200 mmol) with the 
uridine 5′-monophosphomorpholidate 4-morpholine-N,N′-dicyclohexylcarboxamidine salt (224 mg, 
0.326 mmol), 1-methylimidazole hydrochloride (128 mg, 1.08 mmol), and NEt3 (55.8 L, 0.400 
mmol) in DMF (3.92 mL) in a 25-mL round-bottom flask at r.t. for 12 h.56 The tri-O-acetylated UDP-
sugar was purified by column chromatography on C-18 silica gel and then preparative HPLC on C-18 
silica gel. The compound was dissolved in MeOH/water/NEt3 (5 mL, 5:2:1) in a 25-mL round-bottom 
flask, and the reaction mixture was stirred at r.t. overnight. The product was purified by preparative 
HPLC on C-18 silica gel. Finally, the purified compound was passed through a Bio-Rad AG® 50W-
X8 resin (Na+ form) and lyophilized.
Route 2: N-Hydroxysuccinimide (NHS) esters were prepared according to a literature procedure.67 A 
solution of the NHS ester (0.150 mmol) in DMF (1.08 mL) was added to a mixture of UDP-D-
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galactosamine disodium salt (30.5 mg, 0.0500 mmol) in HEPES buffer (0.1 M, pH = 8.0; 1.08 mL) at 
0 C. The reaction mixture was allowed to warm to r.t. and stirred overnight. Next, the mixture was 
purified by column chromatography on C-18 silica gel and then preparative HPLC on C-18 silica gel. 
Finally, the purified compound was passed through a Bio-Rad AG® 50W-X8 resin (Na+ form) and 
lyophilized.
Experimental procedure for the preparation of peptides (Figure 2A). Peptide-1 and -2: Peptides 
were synthesized on 2-chlorotrityl chloride resin by solid phase peptide synthesis using N-Fmoc-
protected amino acids. Each coupling step was performed with N-Fmoc-protected amino acid (10 
equiv.), COMU® (10 equiv.), and N,N-diisopropylethylamine (20 equiv.) in DMF at r.t. for 30 min 
under N2 agitation. Fmoc deprotection was conducted with 20% piperidine in DMF at r.t. for 20 min 
under N2 agitation. The N-terminus was reacted with (S)-2-((5-fluoro-2,4-
dinitrophenyl)amino)propanamide (10 equiv.) and N,N-diisopropylethylamine (10 equiv.) in DMF at 
r.t. overnight under N2 agitation. Peptides were cleaved and deprotected by a mixture of 
trifluoroacetic acid (88% v/v), triisopropylsilane (2% v/v), 1,4-dithiothreitol (5% w/v), and water (5% 
v/v) at r.t. for 1.5 h. The mixture was concentrated, triturated with cold Et2O, redissolved in water, 
and lyophilized. The desired peptide was purified by preparative HPLC on C-18 silica gel. Peptide-3: 
N-(9-Fluorenylmethyloxycarbonyl)-O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranosyl)-L-threonine was prepared according to literature procedures.68–70 Peptides were 
synthesized on 2-chlorotrityl chloride resin by solid phase peptide synthesis using N-Fmoc-protected 
amino acids. Each coupling step was performed with N-Fmoc-protected amino acid (10 equiv.), 
COMU® (10 equiv.), and N,N-diisopropylethylamine (20 equiv.) in DMF at r.t. for 30 min under N2 
agitation. For the reaction with the glycosylated amino acid, the coupling reaction was conducted with 
N-(9-fluorenylmethyloxycarbonyl)-O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranosyl)-L-threonine (2 equiv.), COMU® (2 equiv.), and N,N-diisopropylethylamine (4 
equiv.) in DMF at r.t. overnight under N2 agitation. Fmoc deprotection was conducted with 20% 
piperidine in DMF at r.t. for 20 min under N2 agitation. The N-terminus was reacted with (S)-2-((5-
fluoro-2,4-dinitrophenyl)amino)propanamide (10 equiv.) and N,N-diisopropylethylamine (10 equiv.) 
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in DMF at r.t. overnight under N2 agitation. Peptides were cleaved and deprotected by a mixture of 
trifluoroacetic acid (88% v/v), triisopropylsilane (2% v/v), 1,4-dithiothreitol (5% w/v), and water (5% 
v/v) at r.t. for 1.5 h. The mixture was concentrated, triturated with cold Et2O, redissolved in water, 
and lyophilized. The crude product was purified by preparative HPLC on C-18 silica gel. For the 
deacetylation of the sugar moiety, purified glycopeptides were treated with aqueous hydrazine (5%) 
for 1 h. The deprotected glycopeptides were purified by preparative HPLC on C-18 silica gel.
Representative procedure for the glycosylation by GalNAc-Ts with UDP-GalNAc or UDP-
GalNAc analogs (Figures 3, S6, 5A, and 5B). The glycosylation reaction was initiated by the 
addition of wild-type or mutant GalNAc-T (-T2 = 50.0 nM; -T1 = 160 nM; or -T10 = 120 nM) in 
Tris-HCl buffer (16.7 mM Tris-HCl, 100 mM NaCl, 25% glycerol, pH = 7.4; 25.0 L) to the mixture 
of UDP-sugar (500 M), and peptide (Peptide-1, Peptide-2, or Peptide-3; 100 M) in Tris-HCl buffer 
(25 mM Tris-HCl, 20 mM MnCl2; 25.0 L) at 0 C, resulting in a final reaction mixture containing 
GalNAc-T (-T2 = 25.0 nM; -T1 = 80.0 nM; -T10 = 60.0 nM), peptide (Peptide-1, Peptide-2, or 
Peptide-3; 50.0 M), UDP-sugar (250 M) in Tris-HCl buffer (20.8 mM Tris-HCl, 10 mM MnCl2, 50 
mM NaCl, 12.5% glycerol, pH = 7.4; 50.0 L). The glycosylation was conducted at 37 C for 1 h (-
T2; -T10) or 2 h (-T1) and quenched by the addition of aqueous EDTA (150 mM, pH = 8.0; 25.0 L). 
Glycopeptide formation was determined by HPLC and peak integration. 
Michaelis–Menten kinetics, UDP-sugar competition experiments, and glycosylation of natural peptide 
substrates including mass spectrometry-based sequencing are described in the Supporting 
Information. 
Further details can be found in the Supporting Information.
Safety statement: No unexpected or unusually high safety hazards were encountered.
Associated Content
Supporting Information
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Additional experimental details, data, and figures and tables including crystal structure modeling 
(Figures  S1 and S3), GalNAc-T multiple sequence alignment (Figure S2; Table 1), enzymatic activity 
screens (Figures S4, S5, and S6), GalNAc-T cloning and expression data (Table S2; Figure S7), 
kinetics graphs, MS/MS spectra, synthetic schemes, and NMR spectra. 
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